Revised response criteria for malignant lymphoma.
- B. Cheson, B. Pfistner, V. Diehl
- Medicine, BiologyJournal of Clinical Oncology
- 10 February 2007
New guidelines incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma are presented and it is hoped that they will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
- Michael L. Wang, S. Rule, K. Blum
- MedicineNew England Journal of Medicine
- 7 August 2013
Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
- E. Hoster, M. Dreyling, M. Unterhalt
- MedicineBlood
- 16 November 2006
The MIPI is the first prognostic index particularly suited for MCL patients and may serve as an important tool to facilitate risk-adapted treatment decisions in patients with advanced stage MCL.
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage…
- W. Hiddemann, M. Kneba, M. Unterhalt
- MedicineBlood
- 1 December 2005
Adding rituximab to CHOP significantly improves the outcome for patients with previously untreated advanced-stage FL and does not induce major adverse effects.
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
In this single-group, open-label, phase 2 study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment.
The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family.
- M. Dreyling, J. Martinez-Climent, M. Zheng, J. Mao, J. Rowley, S. Bohlander
- BiologyProceedings of the National Academy of Sciences…
- 14 May 1996
The identification of the CALM/AF10 fusion gene in the widely used U937 cell line will contribute to the understanding of the malignant phenotype of this line.
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
- B. Eichhorst, M. Hallek, M. Dreyling
- MedicineAnnals of Oncology
- 2010
Of 000/ 000/year at age > age at is 69 years; 14% of CLL patients are younger than 55 and the average age of patients with CLL is 55.
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients…
- G. Lenz, M. Dreyling, W. Hiddemann
- Medicine, BiologyJournal of Clinical Oncology
- 20 March 2005
The combined immunochemotherapy with R-CHOP resulted in a significantly higher response rate and a prolongation of the TTF as compared with chemotherapy alone, and may serve as a new baseline regimen for advanced stage MCL.
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma:…
- M. Dreyling, G. Lenz, W. Hiddemann
- Medicine, BiologyBlood
- 16 November 2004
Early consolidation by myeloablative radiochemotherapy followed by ASCT is feasible and results in a significant prolongation of PFS in advanced-stage MCL, and longer follow-up is needed to determine the effect on OS.
...
...